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Abstract
Purpose: Tumor treating ﬁelds (TTFields) is a novel antimitotic treatment that was ﬁrst proven effective for glioblastoma multiforme, now with trials for several extracranial indications underway. Several studies focused on concurrent TTFields therapy with
radiation in the same time period, but were not given simultaneously. This study evaluates the targeting accuracy of simultaneous
radiation therapy while TTFields arrays are in place and powered on, ensuring that radiation does not interfere with TTFields and
TTFields does not interfere with radiation. This is one of several options to enable TTFields to begin several weeks sooner, and
opens potential for synergistic effects of combined therapy. Methods: TTFields arrays were attached to a warm saline water bath
and salt was added until the TTFields generator reached the maximal 2000 mA peak-to-peak current. A ball cube phantom containing
2 orthogonal ﬁlms surrounded by ﬁducials was placed in the water phantom, CT scanned, and a radiation treatment plan with 58 isocentric beams was created using a 3 cm circular collimator. Fiducial tracking was used to deliver radiation, the ﬁlms were scanned, and
end-to-end targeting error was measured with vendor-supplied software. In addition, radiation effects on electric ﬁelds generated by
the TTFields system were assessed by examining logﬁles generated from the ﬁeld generator. Results: With TTFields arrays in place
and powered on, the robotic radiosurgery system achieved a ﬁnal targeting result of 0.47 mm, which was well within the submillimeter
speciﬁcation. No discernible effects on TTFields current output beyond 0.3% were observed in the logﬁles when the radiation beam
pulsed on and off. Conclusion: A robotic radiosurgery system was used to verify that radiation targeting was not adversely affected
when the TTFields arrays were in place and the TTFields delivery device was powered on. In addition, this study veriﬁed that radiation
delivered simultaneously with TTFields did not interfere with the generation of the electric ﬁelds.
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Introduction
Glioblastoma multiforme (GBM) has a very poor prognosis
with a median survival time of 14 to 15 months,1,2 using standard therapy with concurrent postoperative radiotherapy and oral
chemotherapy for 6 weeks, followed by maintenance chemotherapy. Recently, the novel approach of tumor treating ﬁelds
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(TTFields) utilized after completion of radiotherapy has been
demonstrated to improve survival outcomes in a randomized
trial.3 For patients not enrolled in clinical studies, the current
clinical treatment paradigm is to ﬁrst complete 6 weeks of radiation therapy, followed with TTFields therapy concurrent with
maintenance Temozolomide (TMZ). Preclinical data suggest
that using TTFields concurrently with radiotherapy treatment
may further improve outcome.4 We have previously determined
that with the TTFields arrays in place but powered off, radiation
dosimetry is appropriate5 and that it is possible to accurately
target a head phantom by using a cone-beam CT for alignment.6,7 In this work, a dedicated robotic radiosurgery system
is used to assess idealized accuracy and stability of radiation targeting through the arrays while TTFields are being delivered.
The role of radiosurgery for GBM has previously been
reviewed8 and is not the topic of this paper, but the accuracy
of radiation delivered through TTFields is best measured by
stereotactic systems because of their improved accuracy.
TTFields acts as an antimitotic treatment method that works
by delivering electric ﬁelds in the frequency range of 100 to
300 kHz via ceramic transducer arrays placed directly on the
skin.9 Cell line studies have shown that TTFields may interfere
with the assembly of spindle microtubules in lung adenocarcinoma cells while inducing cellular multinucleation and chromosome segregation.10 Similar phenomena were observed in vivo
in F-98 glioma cells.10 In ovarian A2780 cells, TTFields was
shown to induce apoptosis in actively dividing tumor cells.10
TTFields is also currently being investigated as a therapy
for treating several extracranial indications such as mesothelioma (NCT02397928) which has completed,11 lung
(NCT02973789),12 pancreas (NCT03377491),13 hepatocellular
(NCT03606590),14 and ovarian cancer (NCT03940196).15
A randomized phase 3 clinical trial EF-14 showed that
TTFields with maintenance TMZ therapy resulted in improvement in progression-free survival and overall survival in
newly diagnosed GBM patients. In the patient group treated
with TMZ plus TTFields, median progression-free survival
was 6.7 months (95% CI 6.1-8.1) compared to 4 months
(95% CI 3.8-4.4) in patients treated with TMZ alone with a
40-month median follow-up period.3 This study also showed
that there were no clinically signiﬁcant differences in side
effects in both groups. A study by Ballo et al16 examined the
effect of ﬁeld strength17 in a simulation-based study of 340
patients from the EF-14 study by combining factors of power
density and compliance into a single measure of dose. These
researchers showed a correlation between TTFields dose
density (product of average power density in the tumor and
device usage) and overall patient survival. Patients with dose
density >0.770 mW/cm3 had a longer progression-free survival
of 8.5 months compared to 6.7 months in patients with dose
density <0.770 mW/cm3. Patients with both power density
>1.15 mW/cm3 and device usage >75% had a median overall
survival increase of 4 months over patients with power
density <1.15 mW/cm3 and device usage <75%.16
The combined treatment of TTFields, radiotherapy and TMZ
following tumor resection was found to be safe and well-
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tolerated.18 In the study of Li et al,19 the presence of TTFields electrodes demonstrated only a very minor impact on the radiotherapy
dose delivered to the target site, but large differences at the skin
surface. When the ceramic electrodes were left in place but
powered off during radiation treatment, 80% of patients developed
local dermatological complications graded as CTCAE grade 1 to
2, but no grade 3 or higher toxicities were encountered.20
Recommendations on scalp saving measures were advised.5,19,20
Concurrent TTFields therapy with radiation is deﬁned as
both therapies delivered during the same period of time but
not given simultaneously. To differentiate from prior studies
on concurrent therapy, we deﬁne “simultaneous” as delivering
both therapies at the same time, with the TTFields device
powered on while the radiation beam is on. Karanam et al4
have hinted at potential synergisms of TTFields and simultaneous radiation therapy, and simultaneous therapies would be one
of several options to enable patients to receive TTFields several
weeks sooner than in the current clinical paradigm.18,19,21
However, before the 2 therapies could be delivered simultaneously, it is necessary to determine if either therapy interferes
with the accuracy of the other.
The purpose of this work is to examine the targeting accuracy of treating central nervous system (CNS) and stereotactic
body radiation therapy (SBRT) patients with simultaneous
TTFields and radiation therapy on a robotic radiosurgery platform with skull tracking or ﬁducial tracking. In the Stachelek
et al5 study, radiation dosimetric effects from the TTFields
arrays were analyzed by ﬁrst scanning a head phantom
without the arrays, and then comparing radiation treatment
plans calculated on the nonTTFields array phantom to those
recalculated with the arrays in place. In a similar strategy, the
skull tracking tests in the present study use a CT scan of the
phantom without the arrays in place as the reference, to
compare the potential effects in targeting if the arrays were
added in various positions at the time of treatment.
The ﬁrst concern we address in this work is to determine if
the ceramic disks inhibit the ability to accurately target the radiation, especially if skull tracking is used. The ceramic disks are
close to the density of bone and therefore are very clearly visible
in the stereoscopic x-rays used for localization. This means that
before skull tracking with the robotic radiosurgery platform
could be used for patients, steps would need to be taken to
ensure that excessive target localization errors could be prevented. Therefore, ﬁducial tracking was used for the actual
end-to-end measurement in this study, which would be applicable to the extracranial body sites which are currently being
investigated for TTFields.11–15 This is a preliminary phantom
study to assess the targeting of patients wearing the electrodes
and to examine the effect of the radiation environment on the
TTFields generator and the ﬁelds in-situ.

Materials and Methods
The methods and results are both separated into 2 parts: (1) a series
of skull tracking feasibility tests consisting of imaging only and (2)
a ﬁducial tracking end-to-end measurement.
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Skull Tracking Feasibility Tests on Head Phantom
The TTFields arrays are repositioned on a weekly basis for
patients, so in order to test localization, the anthropomorphic head phantom22 was CT scanned without any of the
ceramic electrodes in place; 0.625 mm thin slices were
used. When the phantom was on the treatment table as in
Appendix Figure A1, the arrays were taped in place for
ease of repositioning. A series of imaging tests were
taken, as in Appendix Figure A2, to assess the potential
effects on skull tracking each time the TTFields array position was changed.
The skull tracking treatment plan was CT scanned several
months before we obtained the TTFields arrays; we simply
used the normal monthly quality assurance skull tracking
end-to-end plan for the dedicated robotic stereotactic system.
This method completely eliminated any inﬂuence of the
TTFields arrays on the treatment plan, because the plan was
created before the arrays were placed on the phantom. As can
be seen in Figure A1, the TTFields system consists of 4 separate
arrays, 1 on the posterior, 2 on the sides, and 1 on the superior
portion of the head. Initially, only the posterior array was afﬁxed
to the head phantom, since the posterior array could not be repositioned without moving the head phantom. The head phantom
was then placed on the treatment table and aligned using skull
tracking image guidance. For the entirety of all skull tracking
tests, the posterior array and head phantom remained in this
exact position, while the other 3 arrays were taped on in
various positions, and skull tracking images were taken for
each position of the 3 movable arrays, to determine any potential
effects on the targeting accuracy. No end-to-end targeting measurements were performed with skull tracking, because methods
to ensure the prevention of large targeting errors would be
needed before it could be considered for patients.

Fiducial Tracking End-to-End Measurement of Ball Cube
in Water Phantom
In addition to the skull tracking tests, ﬁducial tests were also performed because both hypofractionated treatments and TTFields
have been used extracranially, since body arrays are also available.11–15 For this test, we wanted to target not only based on
ﬁducials but also to examine the effects of the radiation environment on the TTFields system. This study used a dedicated
robotic radiosurgery platform to deliver a typical radiation
plan to a phantom that was designed to mimic the clinical situation of a patient with implanted ﬁducials receiving simultaneous
TTFields and radiation therapy. The standard for end-to-end
accuracy measurement of robotic radiosurgery is the ball cube
phantom22 as shown in Figure 1, which holds 2 orthogonal
sheets of 2.5 × 2.5 inch Gafchromic ﬁlm. The target in the
center of the cube is a 3-cm diameter sphere which is 12%
denser than water so it is visible on CT scan and can be delineated as the target, as seen in Figure 2.
It is worth noting that the TTFields generator measures the
“skin temperature” and will shut the generator off and sound
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an alarm if the temperature drops much below that of normal
human skin (33 °C), as a safety mechanism in case the array
comes loose from a patient. In addition, the generator checks
the impedance, also alarming and shutting the generator off if
the impedance is not in the normal range. In contrast to the
skull tracking tests that used an existing treatment plan for the
ﬁducial tracking test, the phantom was scanned, planned, and
irradiated within an hour to ensure the water temperature
remained within the allowable range to avoid these alarms.
To achieve this, ﬁrst, the TTFields arrays were afﬁxed to the
inside edges of the phantom as in Figure 2, then the container
was ﬁlled with warm water, at approximately 38 °C, and a small
amount of salt was added initially. The ceramic TTFields disks
were then connected to the TTFields generator, and as the water
was stirred, salt was slowly added until the impedance across
each pair of TTFields arrays through the saline bath was approximately 100 Ω and the TTFields software showed the maximal
current of 2000 mA, peak-to-peak (amplitude of 1000 mA) in all
arrays. A plastic red 16-ounce cup (part number P16RCT, Solo
Cup Company) was used as a platform to position the cube in
the middle of the phantom. The cup was trimmed shorter in
order to customize the height of the ball cube in the center of the
saline bath, and the cup was left in the same position throughout
the entire procedure. The ball cube phantom was then submerged
in the water tank, and pieces of solid water were placed on the
top of the cube to keep the cube submerged.1 The entire assembly
was taken to the CT scanner for the planning scan.
The CT was acquired using 0.625 mm slice thickness and
subsequently imported to the Precision treatment planning
system, where the target was delineated. The ball cube
phantom has embedded gold ﬁducials, and in the planning
process these ﬁducials are identiﬁed so that the delivery
system tracks these for targeting (Figure 2). A treatment plan
was developed using a 3 cm ﬁxed cone, optimized to conform
to the target per our standard end-to-end test procedures.22
Delivery of the treatment by a CyberKnife S7 is shown in
Figure 3; the plan consisting of 58 isocentric beams with 6
Megavoltage ﬂattening ﬁlter-free photons took less than
20 minutes to irradiate. During the treatment (end-to-end
test), the TTFields electrodes were in place and powered on
while the radiation was simultaneously being delivered. The
orthogonal ﬁlms were removed from the phantom, scanned,
and analyzed with the vendor-supplied end-to-end software to
assess the accuracy of the alignment (Figure 4).

Results
Skull Tracking Feasibility Tests on Head Phantom
A series of stereoscopic x-ray images were taken with the
phantom in a ﬁxed known position as shown in Figures A1 to
A2, to quickly assess the effects of array position on the targeting accuracy without performing full end-to-end tests. Since the
posterior TTFields array could not be moved without moving
the phantom, it was left in place throughout all of these tests.
Table A1 shows the reference position of the phantom, which
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Figure 1. End-to-end targeting tests using the Accuray anthropomorphic phantom, showing insertion of 2 perpendicular pieces of ﬁlm.

was determined by averaging 5 stereoscopic images with only
the posterior array in place.
The phantom was left in this same position throughout the
remaining tests, therefore any subsequent measurement in
excess of 0.1 mm or 0.1° may be considered as a targeting
error. At the end of the series of measurements, another ideal
set of images like this were taken, verifying that the phantom
was not inadvertently moved by more than 0.1 mm or 0.1°.
In the next series of tests, the anterior array was added. In each
of the 3 positions of the anterior array, 2 sets of stereoscopic
images were taken and compared to each other, as may be seen
in Table A2. The phantom and the posterior TTFields array
remained in the same position as when the tests in Table A1
were performed. Ideally, the Brightness and Gradient metrics for
both images A and B should all be 1.00. In Table A1, it may be
seen that the Brightness was only 1% less than ideal when the posterior TTFields array was in place, but that the Gradient was 2% to
4% lower than ideal. In Table A2, with both the anterior and posterior array in the image, the Brightness was 4% to 5% lower than
ideal and the Gradient was about 25% lower. The shifts and rotations in Table A2 are quite similar to those in Table A1, but the
large difference in Brightness and Gradient may indicate that the
tracking algorithm is beginning to have difﬁculty.
Tables A3 and A4 show results of the ﬁnal skull tracking
tests, in which the full TTFields arrays were placed on the

phantom, with the phantom still remaining in the same reference position as in the other tests. The last column in
Table A4 has a 3D Euclidean distance approaching half a millimeter from the median reference position of Table A1, from
imaging alone without an end-to-end test, which is sufﬁciently
large to indicate the need for further investigation before skull
tracking would be used on patients.
In the ﬁrst 2 rows of Table A3, the imaging technique was
the same as for all images in Tables A1 and A2, which for
Imager A was 109 kV, 100 mA, 100 msec and for Imager B
was 106 kV, 100 mA, 100 msec. In the middle 2 rows of
Table A3, energy was changed to 100 kV for both imagers,
and in the last 2 rows, it was set to 120 kV. Brightness and
Gradient varied greatly among the tests in Table A3.

Fiducial Tracking End-to-End Measurement of Ball Cube
in Water Phantom
The duration of the entire ﬁducial tracking radiation treatment
was 10 min and 38 s to deliver all 58 isocentric beams with a
3-cm ﬁxed cone. During the treatment saline bath remained
within the allowable temperature and impedance range the
entire time without any alarms from the TTFields system.
Graphs from the TTFields system in Figure 5 shows that

Biswas et al

5

Figure 2. Treatment planning system view of tumor treating ﬁelds (TTFields) arrays surrounding the saline water bath with the ball cube
phantom inside. In the upper portion of the ﬁgure (A) and (B) are 2 oblique images of the phantom with the ceramic electrodes clearly visible. The
ﬁducials used for alignment are identiﬁed by the purple target marks. On the bottom of the ﬁgure, axial, sagittal, and coronal views have the
isodose lines superimposed on the cube phantom in the water bath.

there were no discernible effects on TTFields current output
recorded in the logﬁles when the radiation beam pulsed on
and off, with the reported current in both channels remaining
within 1998 to 2004 mA (peak-to-peak) throughout the entire
irradiation.
The submillimeter end-to-end targeting accuracy speciﬁcation was met, and the ceramic electrodes did not inhibit the targeting of the dedicated robotic radiosurgery system. Even when
delivering radiation through the TTFields arrays simultaneously
while the arrays were powered on, a submillimeter targeting
result of 0.47 mm was achieved (Figure 4). The ∼200 kHz
TTFields signal did not adversely affect the targeting beyond
the submillimeter accuracy speciﬁcation. Based on the ﬁlm
analysis of the end-to-end test the root-mean-square targeting
error was 0.47 mm.

Discussion
TTFields is one of the modern treatment options for GBM. The
beneﬁt of TTFields therapy following standard chemoradiation
for GBM has been demonstrated by randomized clinical trials

resulting in signiﬁcant overall and progression-free survival.3,16
There is speculation that the simultaneous delivery of TTFields
and radiation may be synergistic,4 so the purpose of the present
phantom study was to ﬁrst test targeting effects.
As expected, the overall targeting has not changed. The ﬁducial tracking result still met the standard targeting speciﬁcation
even with the TTFields electrodes in place and powered on. For
skull tracking treatments, more work on the localization needs
to be done to ﬁnd the best method for the targeting system to
ignore the electrodes, particularly the potential impact of the
large changes to Brightness and Gradient metrics in Tables
A1 to A3 would need to be thoroughly explored. The thickness
of each ceramic disk is 1 mm, but this does not necessarily represent the maximal induced targeting inaccuracy because they
are denser than bone. If the patients were to be scanned with
the array in place, there would be a substantial photon starvation
artifact (streaking) that would hamper the ability for the tracking algorithm to properly function. A more thorough investigation on the potential effects on the tracking algorithm would be
advisable before skull tracking with TTFields arrays is used
clinically. In the clinical setting, the electrodes would not be

6

Technology in Cancer Research & Treatment

Figure 3. Delivery of simultaneous tumor treating ﬁelds (TTFields) during radiation on the robotic radiosurgery platform using ﬁducial tracking.
(A) Saline bath with ball cube phantom on the treatment table with the TTFields arrays powered on. (B) Live tracking views on the robotic
radiosurgery system console.

anticipated to be distributed on the patient exactly the same
way every day making this targeting more challenging.
Furthermore, the TTFields system has certain temperature
and impedance requirements that were more feasible to
achieve in a nonanthropomorphic phantom which could not
be targeted with skull tracking. Therefore, ﬁducial tracking
was used for the end-to-end measurement in this paper, and
although potential feasibility of skull tracking was shown, a
much more exhaustive series of tests would need to be done
before safety for patients could be ensured, which is beyond
the scope of this paper.
The submillimeter end-to-end speciﬁcation of the robotic
radiosurgery platform can only be measured explicitly in a
phantom, but several studies have shown similar accuracy in
more realistic environments.23–26 The targeting test in the
present study was a one-time experiment and is not intended
to mandate a new quality assurance procedure. Other more
detailed tests of TTFields simultaneously with radiation are
planned.

For the skull tracking tests, the phantom remained in the
same position for all tests; a more thorough future study
would be to repeat this for various shifts and rotations, but
for initial veriﬁcation, this was a serviceable method. Since
Table A3 showed that Brightness and Gradient varied greatly
as a function of imaging technique when the TTFields arrays
were present for skull tracking, this would need to be more
fully explored with a series of actual end-to-end targeting
tests before use on patients, which is beyond the scope of this
paper, so a ﬁducial tracking end-to-end test was used instead.
There are a few concerns that have been raised regarding
simultaneous delivery. Radiation dose is imparted by photon
interactions that lead to electron cascades in tissue that may
be affected by the alternating TTFields. However, each electron
cascade is very short-lived relative to the frequency of the
TTFields. The mean energy of the ions that ultimately deliver
the dose is ∼34 eV but they interact within 10−9 s. So, there
is potential for the dose distribution to be blurred but because
of the short-lived electrons, this blurring may be difﬁcult to
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Figure 4. The results of the ﬁducial tracking end-to-end test that was delivered to the ball cube phantom in the saline bath while the tumor treating
ﬁelds (TTFields) arrays were powered on.

measure with ﬁlm because the effect is very small. In addition,
the blurring effect is further minimized by the delivery method
because the dose delivery was achieved with 58 unique beam
angles, so the composite dose blurring would be extremely
small and therefore difﬁcult to measure.
Another interplay is related to the dose deposition process.
By generating ion pairs in the medium, we change the impedance of the medium. But in this experiment, the reported
current from the TTFields system remained within 0.3% of a
constant 2000 mA (peak-to-peak). If there was an impedance
shift during the treatment, the TTFields generator seemed
able to adjust adequately. It is worth noting that there was an
observed heating of the phantom during the water phantom
measurements that appear to be consistent with Joule heating.
In a clinical study, 10% to 17% of patients felt a heat sensation,27 indicating that hyperthermia could potentially be
another synergistic effect of the simultaneous therapies,27–30
although this was superﬁcial heating and presumed not to be
heating of the deep tissue. This phenomenon is being studied
in greater detail in our upcoming work, which will also
account for inherent temperature regulation within a patient.
Stachelek et al5 compared radiation plans without the
TTFields arrays to those recalculated with the arrays in place.
Likewise, in the present study, a phantom was CT scanned
without the arrays and skull tracking was tested with the
arrays added. Since the arrays are repositioned on the patient
periodically, the goal of both of these studies is to determine
if the effects of the arrays can average out, for both treatment

planning dosimetry and for the targeting accuracy. Initial treatments for patients may need CT scans without and with the
TTFields arrays for direct comparisons on patients, but if
phantom testing and patient comparisons can ultimately show
that the arrays do not adversely impact the dose distribution
or targeting, then it might eventually be possible to account
for the TTFields array effects in plans that were CT scanned
without the arrays.
For example, the surface dose may be greatly increased
directly below each ceramic disc as shown by Li et al19 but
the dose there is usually already low5 because of skin-sparing
effects of high energy photons and because the average
human skull thickness is 6.5 mm which provides a transition
region from the high dose in the tumor to a lower dose at the
skin. Therefore, although there can be a dramatic percentage
increase of 130% to 260%19 at the surface, the absolute dose
in those regions may remain low.5 Considering all these
effects, a phantom study of 10 consecutive patients treated
for glioblastoma that were recalculated to a cranial
phantom found that dose increases for the highest-dose 1
and 20 cc volumes (D1cc and D20cc) of 5 mm thick skin contours were 3.1%, and skin dose for all 10 cases remained
below clinical dose tolerance levels.5 A clinical study of concurrent TTFields and radiation encountered temporary
grades 1 to 2 skin erythema, dermatitis, or pruritus in 80%
of patients, but no grade 3 toxicity.20 These effects must be
monitored and quantiﬁed thoroughly in upcoming clinical
trials, and when they are more fully understood, it might be
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Figure 5. Data ﬁle from the tumor treating ﬁelds (TTFields) system shows that while the radiation beam was pulsed on and off throughout the
measurement, the maximum peak-to-peak variation in the current per channel was (2004-1998)/2001 = 0.3%.

possible to account for them in plans that were CT scanned
without the arrays.

Conclusion
A robotic treatment system with real-time automated stereoscopic x-ray ﬁducial tracking can be used to successfully
target radiation in a phantom with the TTFields arrays in
place and activated simultaneously while the radiation beam
is on. The end-to-end accuracy speciﬁcation was met, even
when delivering radiation through the TTFields arrays simultaneously while the arrays were powered on, with a ﬁnal targeting
result of 0.47 mm. As shown in Figure 5, no discernible effects
beyond 0.3% on TTFields output current were observed when
the radiation beam pulsed off and on.
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Note
1.

By comparing Figure 3 to Appendix Figure A1 it may be seen that
the bottom slices of solid water from the Accuray head phantom
were used as the “lid” for the saline water bath in Figure 3. The
main purpose of the 1 cm thick 20 × 20 cm slice of CIRS
Plastic Water under the saline bath in Figure 3 was to transport
the assembly from the CT scanner to the treatment table
without inducing any motion within the phantom.
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